298380 - ABL Bio Inc.

298380 Summary
Biopharma
Stock Price & Overview
₩71,400 +3,800 (+5.62%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩71,400  ≈ US$51  ·  Market cap ₩4.0tn (≈ $2.9bn)

Material matter affecting investment judgment (clinical trial plan amendment approved)

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항(임상시험계획변경승인) (이중항체 면역항암제 ABL503의 제1상 임상시험계획 (IND) 변경승인)